Postural Orthostatic Tachycardia Syndrome (POTS) and Ehlers Danlos Syndrome (EDS) in Pediatric Patients
Abstract
Postural orthostatic tachycardia syndrome (POTS) is a disorder of the autonomic nervous system (ANS) that is predominantly found in females and disproportionately affects adolescents. POTS symptoms, including dizziness, fatigue, palpitations, headaches, and difficulty concentrating, are exacerbated by upright posture and tend to improve or resolve with recumbency. Management typically starts with lifestyle recommendations, such as increasing fluid and salt intake in addition to a graduated exercise program, and sometimes includes pharmacologic agents. POTS can significantly impact one&s;s quality of life. POTS is frequently co-morbid with other medical conditions, including Ehlers Danlos syndrome (EDS). EDS, a group of heritable connective tissue disorders, is characterized by hypermobility, skin hyperextensibility, and tissue fragility. EDS is thought to be present in at least 25% of patients with POTS. Establishing the diagnosis of hypermobile EDS and/or hypermobility spectrum disorder (HSD) typically occurs several years after symptom onset. The symptoms of EDS, including pain, fatigue, and functional disability, have a considerable effect on mood and quality of life in patients. A comprehensive treatment approach is usually recommended and includes both non-pharmacologic and pharmacologic interventions. Adequate psychosocial support is crucial to addressing the emotional aspects of living with these invisible, chronic illnesses, particularly for adolescent patients.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.